Open Access<p>Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study</p>
Author(s) -
Yong Wang,
Xiangwen Meng,
Shengyan Zhou,
Yufang Zhu,
Jun Xu,
Rui Tao
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s226804
Subject(s) - medicine , temozolomide , apatinib , tolerability , progression free survival , adverse effect , oncology , regimen , population , gastroenterology , chemoradiotherapy , surgery , radiation therapy , chemotherapy , environmental health
This study aimed to determine the efficacy and tolerability of apatinib plus dose-dense temozolomide (TMZ) as first-line treatment for recurrent glioblastoma (rGBM).